News Releases

Date Title Teaser
08/07/18
Summary ToggleSurmodics to Present at 7th Annual Intellisight Investor Conference

Webcast is Live on Wednesday, August 15 , at 2:30 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 7, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will participate in the 7

08/06/18
Summary ToggleSurmodics Reports Third Quarter Fiscal 2018 Results

Raises Fiscal 2018 Revenue Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 6, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 third quarter ended June 30,

07/31/18
Summary ToggleSurmodics IVD Launches Breakthrough MatrixGuard™ Diluent

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 31, 2018-- Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of MatrixGuard™ Diluent.

07/26/18
Summary ToggleSurmodics to Webcast Third Quarter Fiscal 2018 Earnings Conference Call on August 6

Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 26, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal

05/30/18
Summary ToggleSurmodics to Present at Jefferies 2018 Global Healthcare Conference

Webcast is Live on Friday, June 8 , at 11:30 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 30, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and chief

05/16/18
Summary ToggleSurmodics Announces Leadership Change and Appointment of Interim CFO

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 16, 2018-- Surmodics , Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018 .

05/14/18
Summary ToggleSurmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics’ design, development, hydrophilic coating technology and manufacturing capabilities will advance innovative platform technology EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 14, 2018-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies

05/02/18
Summary ToggleCORRECTING and REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 2, 2018-- The fifth bullet in the Recent Highlights section should read: EPS of $0.11 , Non-GAAP EPS of $0.07 (instead of EPS of $0.11 , Non-GAAP EPS of $0.15 ). The correct figure of $0.07 is represented in the Second Quarter Fiscal 2018 Financial Results

05/02/18
Summary ToggleSurmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 2, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 second quarter, ended March 31, 2018 , and raised financial outlook

04/24/18
Summary ToggleSurmodics to Webcast Second Quarter Fiscal 2018 Earnings Conference Call on May 2

Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 24, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter

04/23/18
Summary ToggleSurmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter

Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 23, 2018-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it

03/15/18
Summary ToggleSurmodics to Present at Upcoming Investor Conferences EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 15, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and chief executive officer, and Andy LaFrence , vice president
02/27/18
Summary ToggleAbbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U.
AGREEMENT COMPLEMENTS AND EXTENDS ABBOTT'S BROAD LINE OF VASCULAR CARE PRODUCTS AND DEMONSTRATES VALUE OF SURMODICS' PROPRIETARY DRUG-DELIVERY AND WHOLE-PRODUCT SOLUTIONS STRATEGY
02/13/18
Summary ToggleSurmodics to Host Virtual Annual Meeting of Shareholders Virtual Meeting on February 21 at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 13, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday,
02/08/18
Summary ToggleSurmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 8, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017 , and updated financial
01/30/18
Summary ToggleSurmodics to Webcast First Quarter Fiscal 2018 Earnings Conference Call on February 8 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 30, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal
01/22/18
Summary ToggleSurmodics Receives 510(K) Clearance for Telemark™ Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug Administration Unique Coiled/Braided Shaft Technology Offers Superior Crossability Proprietary Hydrophilic Coating Provides Best-in-Class Lubricity and Low Particulates EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 22, 2018-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro
11/08/17
Summary ToggleSurmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 8, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and financial outlook for
10/26/17
Summary ToggleSurmodics to Present at Canaccord Genuity Medical Technologies and Diagnostics Forum Webcast is Live on Thursday, November 9 , at 9 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 26, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and
10/26/17
Summary ToggleSurmodics to Webcast Fourth Quarter 2017 Earnings Conference Call on November 8 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 26, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter 2017
10/23/17
Summary ToggleSurmodics Announces First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil® Drug-Coated Balloon Comparing SurVeil ® DCB to Medtronic IN.PACT ® Admiral ® DCB Plan to enroll up to 446 patients at approximately 78 sites EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 23, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced
09/18/17
Summary ToggleSurmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter The company received FDA 510(k) and CE Mark clearance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 18, 2017-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S.
09/13/17
Summary ToggleSix-Month Data from the Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2017 Study met primary endpoint and six-month secondary safety endpoints Results demonstrated primary patency of 100% and significant improvement in measured clinical outcomes EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 13, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and
08/03/17
Summary ToggleSurmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 Guidance EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 3, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 third quarter, ended June 30, 2017.
07/26/17
Summary ToggleSurmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil™ Drug-Coated Balloon Study compares SurVeil™ DCB to Medtronic IN.PACT® Admiral® DCB SurVeil DCB design includes new proprietary coating for interventional treatment of PAD EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 26, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic
07/25/17
Summary ToggleSurmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 25, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal
05/22/17
Summary ToggleSurmodics to Present at Upcoming Investor Conferences EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 22, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and chief executive officer, and Andy LaFrence , vice president
04/27/17
Summary ToggleSurmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 27, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 second quarter, ended March 31, 2017 .
04/18/17
Summary ToggleSurmodics to Webcast Second Quarter 2017 Earnings Conference Call on April 27 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 18, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter
04/17/17
Summary ToggleSurmodics Appoints Lisa Wipperman Heine to Its Board of Directors EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 17, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the addition of Lisa Wipperman Heine to the Company’s Board of Directors, effective on April
03/14/17
Summary ToggleSurmodics to Present at Oppenheimer Healthcare Conference Webcast is Live on Tuesday, March 21 , at 10:55 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 14, 2017-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and
02/09/17
Summary ToggleSurmodics Announces 2017 Annual Shareholders Meeting Virtual Meeting on February 14 at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 9, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that its virtual Annual Meeting of
02/02/17
Summary ToggleSurmodics Reports First Quarter Fiscal 2017 Results GAAP Revenue of $17.8 Million , up 7%; Medical Device increase 12% GAAP EPS of $0.17 , Non-GAAP EPS of $0.19 Raises Revenue and EPS Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 2, 2017-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies
01/24/17
Summary ToggleSurmodics to Webcast First Quarter 2017 Earnings Conference Call on February 2 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 24, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal
11/22/16
Summary ToggleSurmodics to Attend Piper Jaffray Healthcare Conference Webcast is Live on Tuesday, November 29 , at 11:30 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 22, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and
11/16/16
Summary ToggleSurmodics Reports Fourth Quarter Fiscal 2016 Results GAAP Revenue of $18.2 Million , up 5% GAAP EPS of $0.20 , Non-GAAP EPS of $0.26 Core Business Performs Well as Key Strategic Growth Priorities Advance Fiscal 2017 Revenue and EPS Guidance Outlined EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 16, 2016-- Surmodics, Inc.
11/09/16
Summary ToggleSurmodics to Present at Canaccord Genuity Medical Technology and Diagnostics Forum Webcast is Live on Thursday, November 17 , at 8:20 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 9, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and
11/08/16
Summary ToggleSurmodics to Webcast Fourth Quarter and Fiscal Year 2016 Earnings Conference Call on November 16 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 8, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter and
10/31/16
Summary ToggleSurmodics Announces Launch of Serene® Single-Coat (SC) Solutions Offering Unmatched Lubricity and Durability to a Broader Range of Device Applications EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 31, 2016-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced the launch of a single-coat formulation of its most advanced hydrophilic medical device coating,
08/16/16
Summary ToggleSurmodics to Present at 5th Annual InvestMNt Conference on August 24 Webcast is Live at 8:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 16, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that the Company will present at the 2016 InvestMNt
08/01/16
Summary ToggleSurmodics IVD Launches Breakthrough StabilBlock® Immunoassay Stabilizer EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 1, 2016-- Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of StabilBlock ® , its most advanced Immunoassay Stabilizer.
07/28/16
Summary ToggleSurmodics Reports Third Quarter Fiscal 2016 Results GAAP Revenue of $20.0 Million , up 25% GAAP EPS of $0.30 , Non-GAAP EPS of $0.37 Core Business Performs Well as Key Strategic Growth Priorities Advance Raises Fiscal 2016 Revenue and EPS Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 28, 2016-- Surmodics, Inc.
07/20/16
Summary ToggleSurmodics to Webcast Third Quarter 2016 Earnings Conference Call on July 28 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 20, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal
06/13/16
Summary ToggleSURMODICS, INC. TO INVEST €9.5M IN R&D, €7.0M IN FACILITY DEVELOPMENT AND CREATE 100 NEW JOBS FOLLOWING ACQUISITION OF CREAGH MEDICAL LTD. IN BALLINASLOE, CO. GALWAY June 13th 2016 ‐ Ballinasloe, Co. Galway . Minister for Jobs, Enterprise & Innovation Mary Mitchell O'Connor TD today announced the creation of 100 new jobs by Lifesciences technologies company Surmodics. It follows the company's acquisition of Creagh Medical in Ballinasloe Co.
06/01/16
Summary ToggleSurmodics to Present at Jefferies Healthcare Conference Webcast is Live on Tuesday, June 7 , at 4 p.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jun. 1, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj , president and chief executive officer, and Andy
05/02/16
Summary ToggleSurmodics Reports Second Quarter Fiscal 2016 Results GAAP Revenue of $16.7 Million , up 16%, Third Consecutive Quarter of Double-Digit Growth GAAP EPS of $0.06 , Non-GAAP EPS of $0.20 SurVeil™ Drug-Coated Balloon Commences IDE Study Raises Revenue and Non-GAAP EPS Guidance Ranges EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 2, 2016-- Surmodics, Inc.
04/28/16
Summary ToggleSurmodics to Webcast Second Quarter 2016 Earnings Conference Call on May 2 Webcast is Live at 4 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 28, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal
04/06/16
Summary ToggleSurmodics Announces First Patient Enrolled in IDE Study of SurVeil™ Drug-Coated Balloon EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 6, 2016-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical devices and in vitro diagnostic technologies, today announced enrollment of the first patient in an early feasibility study of its proprietary SurVeil™ drug-coated balloon (DCB).
02/16/16
Summary ToggleSurmodics to Host Virtual Shareholder Meeting on February 17 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 16, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting
01/28/16
Summary ToggleSurmodics Reports First Quarter Fiscal 2016 Results GAAP Revenue of $16.5 Million , up 16% GAAP EPS of $0.19 , Non-GAAP EPS of $0.38 Fiscal 2016 Guidance Reaffirmed EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 28, 2016-- SurModics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare
01/21/16
Summary ToggleSurmodics to Webcast First Quarter 2016 Earnings Conference Call on January 28 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 21, 2016-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter fiscal
01/11/16
Summary ToggleSurmodics Acquires NorMedix, a Design and Development Company Focused on Minimally Invasive Catheter Technologies Furthers transformation strategy with vascular expertise and R&D capabilities Brings unique catheter-based technology and development capabilities Raising revenue guidance to adjusted range of $62 million to $66 million GAAP EPS in range of $0.30 to $0.35 per share; non-GAAP EPS unchanged at
01/08/16
Summary ToggleSurmodics Provides Updated 2016 Guidance GAAP Revenue Anticipated to Range from $60.0 Million to $64.0 Million Expects GAAP Earnings Per Share of $0.38 to $0.43 per share Expects Non-GAAP EPS of $0.66 to $0.75 per share EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 8, 2016-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical
01/07/16
Summary ToggleSurmodics to Webcast Updated Fiscal 2016 Financial Guidance Conference Call on January 8 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 7, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast on Friday, January 8 , at
12/22/15
Summary ToggleSurModics Announces Device Veteran Shawn McCormick Joins Board of Directors EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Dec. 22, 2015-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced the addition of a new independent board member, Shawn McCormick , a highly experienced medical device executive.
12/01/15
Summary ToggleSurModics to Present at Oppenheimer Healthcare Conference Webcast is Live on Tuesday, December 8, at 10:55 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Dec. 1, 2015-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj , president and chief executive officer, and
11/20/15
Summary ToggleSurModics Acquires Creagh Medical, a Developer and Manufacturer of Balloon Catheters Accelerates strategic transformation into a whole-product solutions provider Significantly advances company’s drug-coated balloon development and manufacturing capabilities Expands pipeline of product development opportunities EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 20, 2015-- SurModics, Inc.
11/11/15
Summary ToggleSurModics to Present at Canaccord Genuity Medical Technology and Diagnostics Forum Webcast is Live on Thursday, November 19 , at 11:40 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 11, 2015-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president
11/10/15
Summary ToggleSurModics Reports Fourth Quarter Fiscal 2015 Results GAAP Revenue Growth of 13% to $17.4 Million and GAAP EPS of $0.22 Non-GAAP Revenue Up 8% and Non-GAAP EPS of $0.30 FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon Increase in Share Repurchase Authorization to $30.0 Million Fiscal 2016 Guidance Outlined EDEN PRAIRIE,
11/04/15
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2015 Earnings Conference Call on November 10 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 4, 2015-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter and
10/05/15
Summary ToggleSurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon Important milestone in moving toward DCB clinical trials in the U.S. SurVeil™ DCB design includes new, proprietary coating for interventional treatment of PAD Advances SurModics’ strategic transformation to a whole-product solutions provider EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct.
08/05/15
Summary ToggleSurModics Reports Third Quarter Fiscal 2015 Results GAAP Revenue Growth of 9% to $15.9 Million and GAAP EPS of $0.30 versus $0.26 Medical Device Business Revenue up 8%; IVD up 13% Continued Progress Developing Our Drug Coated Balloon Platform Raises Fiscal 2015 Revenue and EPS Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug.
07/28/15
Summary ToggleSurModics to Webcast Third Quarter 2015 Earnings Conference Call on August 5 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 28, 2015-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter
07/23/15
Summary ToggleSurModics to Present at the InvestMNt Conference on August 5 Webcast is Live at 1:10 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 23, 2015-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that the Company will present at the 2015 InvestMNt
05/27/15
Summary ToggleSurModics to Present at Jefferies Healthcare Conference Webcast is Live on Wednesday, June 3 , at 8:30 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 27, 2015-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president and
04/30/15
Summary ToggleSurModics Reports Second Quarter Fiscal 2015 Results GAAP Revenue Growth of 6% to $14.4 Million and GAAP EPS of $0.23 IVD Business Unit Revenue up 23%; Medical Device Revenue up 1% Continued Investment in Transformative Strategy Strong Year to Date Cash Flow from Operations Reaffirms Fiscal 2015 Revenue, EPS and Cash Flow Guidance EDEN PRAIRIE, Minn.
04/21/15
Summary ToggleSurModics to Webcast Second Quarter 2015 Earnings Conference Call on April 30 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 21, 2015-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter
03/18/15
Summary ToggleSurModics IVD Part of Breakthrough Smartphone-Driven HIV Test EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 18, 2015-- SurModics, Inc. (Nasdaq:SRDX) contributed a key component for a diagnostic device that attaches to a smartphone and detects HIV quickly, accurately and inexpensively. “This device is a great example of the benefits of point-of-care diagnostics,
03/06/15
Summary ToggleSurModics Announces New Board Chair EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 6, 2015-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced that Susan E. Knight , a member of the board since 2008, will assume the position of
02/19/15
Summary ToggleSurModics to Present at RBC Capital Markets Global Healthcare Conference Webcast is Live on Tuesday, February 24, at 10 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 19, 2015-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president
02/05/15
Summary ToggleSurModics Announces Gerald B. Fischer’s Retirement from Board of Directors EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 5, 2015-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced that Gerald B. (Jerry) Fischer has retired from the board of directors, effective
02/03/15
Summary ToggleSurModics to Webcast Shareholders Annual Meeting on February 10 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 3, 2015-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting
01/29/15
Summary ToggleSurModics Reports First Quarter Fiscal 2015 Results
01/20/15
Summary ToggleSurModics to Webcast First Quarter 2015 Earnings Conference Call on January 29 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 20, 2015-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter
11/12/14
Summary ToggleSurModics Announces Accelerated Share Repurchase Program EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 12, 2014-- SurModics, Inc. (NASDAQ:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced that it has entered into a $20 million accelerated share repurchase program.
11/06/14
Summary ToggleSurModics Reports Fourth Quarter Fiscal 2014 Results GAAP Revenue of $15.3 Million and GAAP EPS of $0.18 , with non-GAAP EPS of $0.26 from Continuing Operations Design Freeze on Paclitaxel Drug Coated Balloon Development Strong Cash Flow from Operations $30 Million Share Repurchase Program Authorized Fiscal 2015 Revenue, EPS and Cash Flow Guidance
10/30/14
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2014 Earnings Conference Call on November 6 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 30, 2014-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter
08/26/14
Summary ToggleSurModics to Present at CL King's Best Ideas Conference Webcast is Live on Tuesday, September 9, at 11 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 26, 2014-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president
07/31/14
Summary ToggleSurModics Reports Third Quarter Fiscal 2014 Results
07/28/14
Summary ToggleSurModics Expands Protein-Free Stabilizer Line with AP Option EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 28, 2014-- SurModics IVD, Inc. , a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components , is introducing StabilZyme ® Protein-Free AP Stabilizer at the American Association for Clinical
07/22/14
Summary ToggleSurModics to Webcast Third Quarter 2014 Earnings Conference Call on July 31 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 22, 2014-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter
05/01/14
Summary ToggleSurModics Reports Second Quarter Fiscal 2014 Results Total GAAP Revenue of $13.6 Million with Medical Device Segment Revenue Increasing 8% GAAP EPS of $0.18 Includes One-time $0.04 Non-cash Charge Pro Forma EPS Increases 10% to $0.22 Continued Pre Clinical Optimization of Paclitaxel Drug Coated Balloon Full Year 2014 EPS Outlook Range Affirmed and
04/22/14
Summary ToggleSurModics to Webcast Second Quarter 2014 Earnings Conference Call on May 1 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 22, 2014-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter
02/18/14
Summary ToggleSurModics Announces Changes to Board of Directors Ronald Kalich and Timothy Nelson Join SurModics Board, Mary Brainerd Resigns; Company Changes Directors’ Stock Compensation Vesting Period EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 18, 2014-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic
02/18/14
Summary ToggleSurModics to Present at RBC Capital Markets Global Healthcare Conference Webcast is Live on Tuesday, February 25, at 9 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 18, 2014-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president and
01/30/14
Summary ToggleSurModics Reports First Quarter Fiscal 2014 Results GAAP EPS Decreases 10% to $0.26 per share, Reflecting One-Time Events in Each Quarter Pro Forma EPS Increases 17% to $0.21 per share on 5% Pro Forma Revenue Rise in Q1 2014 Investment in Drug Coated Balloon Development Continues Full Year 2014 EPS Outlook Range Raised to $0.85 to $0.97 per share as
01/22/14
Summary ToggleSurModics to Webcast Shareholders Annual Meeting on February 4 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 22, 2014-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting
01/21/14
Summary ToggleSurModics to Webcast First Quarter 2014 Earnings Conference Call on January 30 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 21, 2014-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter
12/04/13
Summary ToggleSurModics to Present at Oppenheimer Healthcare Conference Webcast is Live on Wednesday, December 11, at 8:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Dec. 4, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Andy LaFrence , vice
11/26/13
Summary ToggleSurModics to Present at Piper Jaffray Healthcare Conference Webcast is Live on Tuesday, December 3, at 10:10 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 26, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president
11/12/13
Summary ToggleSurModics to Present at Canaccord Genuity Medical Technology & Diagnostics Conference Webcast is Live on Thursday, November 14, at 1 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 12, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Andy LaFrence , vice
11/05/13
Summary ToggleSurModics Reports Fourth Quarter and Full Year 2013 Results Continuing Operations GAAP EPS Increases 53% to $0.26 on Revenue of $14 .3 million in Q4; EPS Increases 71% for the Fiscal Year Strong Cash Generation in Q4 and Full Year $20 Million Line of Credit Signed Fiscal 2014 Revenue, EPS and Cash Flow Guidance Outlined EDEN PRAIRIE, Minn.
10/29/13
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2013 Earnings Conference Call on November 5 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 29, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter
09/20/13
Summary ToggleSurModics Announces Board Changes Robert C. Buhrmaster to step down as Board Chair at annual meeting in February 2014 ; Current Board member Scott R. Ward to become Chair EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 20, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic
09/03/13
Summary ToggleSurModics Announces Organizational Changes Realignment expected to enhance focus on key growth initiatives EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 3, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced executive leadership
08/27/13
Summary ToggleSurModics to Present at CL King’s Best Ideas Conference Webcast is Live on Thursday, September 12, at 1 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 27, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president
07/31/13
Summary ToggleSurModics Reports Third Quarter Fiscal 2013 Results Continuing Operations GAAP EPS Increases 22% to $0.22 $20 Million Share Repurchase Program Authorized Revenue and EPS Ranges for Full Year Narrowed EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 31, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro
07/29/13
Summary ToggleSurModics IVD Breakthrough Stabilizer Addresses Industry Challenge EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 29, 2013-- SurModics IVD, Inc. , a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components , is launching its new StabilZyme ® Protein-Free Stabilizer today at the American Association for
07/23/13
Summary ToggleSurModics to Webcast Third Quarter 2013 Earnings Conference Call on July 31 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 23, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter
07/22/13
Summary ToggleSurModics to Present at the InvestMNt Conference Webcast is Live on Thursday, August 1, at 8:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 22, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president
05/21/13
Summary ToggleSurModics to Present at the Jefferies Global Healthcare Conference Webcast is Live on Monday, June 3 , at 2:30 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May. 21, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj , president and
05/07/13
Summary ToggleSurModics Reports Second Quarter Fiscal 2013 Results GAAP Revenue Grows 12% Continuing Operations GAAP EPS Increases to $0.23 Non-GAAP Continuing Operations EPS Increases 25% to $0.20 Revenue and EPS Ranges for Full Year Reaffirmed EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May. 7, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface
04/30/13
Summary ToggleSurModics to Webcast Second Quarter 2013 Earnings Conference Call on May 7 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 30, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter
02/11/13
Summary ToggleSurModics' New Low Friction, Low Particulate Device Coatings Introduced SurModics Serene™ hydrophilic coatings address unmet need for lubricious, low particulate medical device coatings EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 11, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification for medical devices, today introduced SurModics Serene™
02/06/13
Summary ToggleSurModics to Webcast Annual Meeting on February 11 EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 6, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday,
01/30/13
Summary ToggleSurModics Reports First Quarter Fiscal 2013 Results 16% GAAP Revenue Growth Continuing Operations Delivered $0.29 GAAP EPS ( $0.22 non-GAAP EPS Adjusting for Gain on Sale of Investment) Full Year 2013 EPS Outlook Range Increased Announces New $10 Million Share Repurchase Program EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 30, 2013-- SurModics, Inc.
01/23/13
Summary ToggleSurModics to Webcast First Quarter 2013 Earnings Conference Call on January 30 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 23, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter
12/21/12
Summary ToggleSurModics Appoints Andy LaFrence as Chief Financial Officer EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Dec. 21, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced the appointment of Andy LaFrence as the company’s Vice President of Finance and Chief
11/06/12
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2012 Results Download Release Fourth Quarter Highlights: GAAP Revenue Declined Slightly; 12% Non-GAAP Revenue Growth Continuing Operations Delivered $0.17 GAAP EPS and $0.19 Non-GAAP EPS Purchased 16.5% of Outstanding Common Stock Full Year Highlights: Achieved Record Hydrophilic Coating Revenue and In Vitro
10/30/12
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2012 Earnings Conference Call on November 6th Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 30, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter
09/11/12
Summary ToggleSurModics Announces Final Results of its Modified Dutch Tender Offer EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 11, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced the final results of its modified Dutch auction tender offer for up to $55.0 million in
09/07/12
Summary ToggleSurModics to Attend CL King's 10th Annual Best Ideas Conference on September 12 EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 7, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today that it will participate in CL King's 10th Annual Best Ideas Conference in New York City on Wednesday, September
09/06/12
Summary ToggleSurModics Announces Preliminary Results of its Modified Dutch Tender Offer EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 6, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced the preliminary results of its modified Dutch auction tender offer for up to $55.0
08/27/12
Summary ToggleSurModics Announces Resignation of Jeffrey Smith from the Board of Directors EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 27, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced that effective August 27, 2012 , Mr. Jeffrey Smith has resigned from SurModics’ Board
08/06/12
Summary ToggleSurModics Announces Commencement of Tender Offer to Purchase up to $55 Million of Its Common Stock EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 6, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced it has commenced a tender offer to purchase up to $55 million of its common stock
08/01/12
Summary ToggleSurModics Plans to Launch Modified Dutch Auction Tender Offer to Purchase up to $55 Million of Its Common Stock EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 1, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced its plan to launch a modified “Dutch auction” tender offer to purchase shares of its
08/01/12
Summary ToggleSurModics Reports Third Quarter Fiscal Year 2012 Results 7% GAAP Revenue Growth; 17% Non-GAAP Revenue Growth Continuing Operations Delivered $0.18 GAAP EPS and $0.17 Non-GAAP EPS Full Year 2012 Outlook Increased EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 1, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro
07/25/12
Summary ToggleSurModics to Webcast Third Quarter 2012 Earnings Conference Call on August 1st Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 25, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter
07/09/12
Summary ToggleSurModics IVD to Launch New Product at AACC in Los Angeles, CA EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 9, 2012-- SurModics IVD Inc. , a wholly owned subsidiary of SurModics, Inc. (Nasdaq: SRDX) and a market leader for in vitro diagnostic assay components , is pleased to announce it will launch BioFX ® TMB Extended Range HRP Microwell Substrate (TMBX) at
05/22/12
Summary ToggleNew Website Reflects Strategic Focus Features Include Online Ordering for Nearly 900 IVD Products EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May. 22, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, is pleased to announce the launch of
05/14/12
Summary ToggleSurModics IVD to Present at Biomarker World Congress in Philadelphia, PA EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May. 14, 2012-- SurModics IVD Inc. , a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for immunoassay reagents for diagnostic tests, is pleased to announce it will present a poster entitled “ Evaluation of Immunoassay Interference
05/08/12
Summary ToggleSurModics Reports Second Quarter Fiscal Year 2012 Results 8% GAAP revenue decline; 4% Non-GAAP revenue growth $0.11 GAAP EPS; $0.14 Non-GAAP EPS Confirms Full Year 2012 Outlook Announces new $50 million share repurchase program EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May. 8, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification
04/25/12
Summary ToggleSurModics to Webcast Second Quarter 2012 Earnings Conference Call on May 8 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Apr 25, 2012 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter 2012 conference call on
04/16/12
Summary ToggleSurModics IVD Launches StabilBlot Blocker Family EDEN PRAIRIE, Minn., Apr 16, 2012 (BUSINESS WIRE) --SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for immunoassay reagents for diagnostic tests used to detect the absence or presence of disease, is pleased to announce the launch of StabilBlot(TM)
03/01/12
Summary ToggleSurModics' Hydrophilic Coating on Medtronic’s Resolute Integrity™ Drug-Eluting Stent Delivery System EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 1, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, announced today that its proprietary hydrophilic technology is being used on Medtronic’s U.S.
02/06/12
Summary ToggleSurModics Reports First Quarter Fiscal Year 2012 Results Year-on-Year Revenue Growth in Key Product Offerings 8% Revenue growth in Hydrophilic Coatings 13% Revenue growth in In Vitro Diagnostics Closed Sale of Pharmaceuticals Assets Affirmed Full Year 2012 Outlook EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 6, 2012-- SurModics, Inc.
02/03/12
Summary ToggleSurModics to Webcast Annual Meeting on February 6 EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 3, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday,
02/03/12
Summary ToggleSurModics Announces Rescheduled Webcast for First Quarter 2012 Earnings Conference Call on February 6 Webcast is Live at 9:00 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 3, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today that it will be hosting a live webcast of its first quarter 2012 conference
02/02/12
Summary ToggleSurModics Announces Preliminary First Quarter 2012 Results EDEN PRAIRIE, Minnesota --(BUSINESS WIRE)--Feb. 2, 2012-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today unaudited preliminary results for the first quarter of fiscal 2012.
01/27/12
Summary ToggleSurModics to Webcast First Quarter 2012 Earnings Conference Call on February 2 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 27, 2012-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter 2012 conference call on
11/22/11
Summary ToggleSurModics to Attend Piper Jaffray's 23rd Annual Health Care Conference on November 29 EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 22, 2011-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today that it will participate in Piper Jaffray’s 23 rd Annual Healthcare Conference in New York City on Tuesday,
11/17/11
Summary ToggleSurModics Completes Sale of Pharmaceutical Assets EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 17, 2011-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today that it has completed the previously-announced sale of its SurModics Pharmaceuticals assets to Evonik Industries
11/03/11
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2011 Results Sequential Revenue Growth in Core Businesses Achieved 2011 Non-GAAP Guidance EDEN PRAIRIE, Minn., Nov 03, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results
11/02/11
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2011 Earnings Conference Call November 3 EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq:SRDX - News), a leading provider of surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter and fiscal year 2011 conference call on Thursday, November 3, at
11/01/11
Summary ToggleSurModics Announces Agreement to Sell Pharmaceutical Assets Achieves Important Milestone towards Returning Company to Sustainable, Long-Term Profitability Enhances Strategic Focus on Core Medical Device and IVD Businesses Creates Compelling Value for All Stakeholders EDEN PRAIRIE, Minn., Nov 01, 2011 (BUSINESS WIRE) -- SurModics, Inc.
09/20/11
Summary ToggleSurModics IVD Introduces A New BioFX(R) TMB Enhanced HRP Membrane Substrate A Winner of the LifeScience Alley (R) 2011 New Technology Showcase! EDEN PRAIRIE, Minn., Sep 20, 2011 (BUSINESS WIRE) -- SurModics IVD introduces BioFX (R) TMB Enhanced HRP Membrane Substrate. SurModics IVD, a wholly owned subsidiary of SurModics, Inc.
09/13/11
Summary ToggleSurModics to Attend CL King's 9th Annual Best Ideas Conference on September 14 EDEN PRAIRIE, Minn., Sep 12, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will participate in CL King's 9 th Annual Best Ideas Conference in New York City on
08/23/11
Summary ToggleSurModics Announces Strategic Realignment of Business - Align cost structure and leadership team to its strategic plan - - Maintain commitment to R&D, core Medical Device and IVD businesses - EDEN PRAIRIE, Minn., Aug 23, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification
08/03/11
Summary ToggleSurModics Reports Third Quarter 2011 Results Raising Earnings Guidance for Full Year Fiscal 2011 EDEN PRAIRIE, Minn., Aug 03, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the third quarter ended
07/28/11
Summary ToggleSurModics to Webcast Third Quarter Fiscal Year 2011 Earnings Conference Call August 3 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Jul 28, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter 2011
07/26/11
Summary ToggleSurModics Introduces New In Vitro Diagnostics Product - SurModics(R) Assay Diluent (Protein-Free) EDEN PRAIRIE, Minn., Jul 26, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, will introduce its SurModics(R) Assay Diluent (Protein-Free) product at the American Association for Clinical
06/15/11
Summary ToggleSurModics Comments on Johnson & Johnson Announcement SurModics re-affirms fiscal 2011 guidance EDEN PRAIRIE, Minn., Jun 15, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, responded to Johnson & Johnson's announcement earlier today that
04/27/11
Summary ToggleSurModics Reports Second Quarter 2011 Results Sequential Revenue Growth in All Three Business Units; Raising Guidance for Full Year Fiscal 2011 EDEN PRAIRIE, Minn., Apr 27, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported
04/20/11
Summary ToggleSurModics to Webcast Second Quarter Fiscal Year 2011 Earnings Conference Call April 27 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Apr 20, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter 2011
02/03/11
Summary ToggleSurModics to Webcast Annual Meeting on February 7 EDEN PRAIRIE, Minn., Feb 03, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday, February 7, at
01/26/11
Summary ToggleSurModics Reports First Quarter 2011 Results EDEN PRAIRIE, Minn., Jan 26, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the first quarter ended December 31, 2010.
01/19/11
Summary ToggleSurModics to Webcast First Quarter Fiscal Year 2011 Earnings Conference Call January 26 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Jan 19, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter 2011
01/05/11
Summary ToggleSurModics and Ramius Reach Agreement Regarding 2011 Annual Meeting of Shareholders Jeffrey C. Smith and David Dantzker, M.D. Appointed to SurModics' Board of Directors; Board Forms Special Committee to Oversee Previously Announced Review of Strategic Alternatives for Pharmaceuticals Business; Ramius Agrees to Support SurModics Director Nominees at 2011 Annual Meeting of
12/14/10
Summary ToggleSurModics Names Gary R. Maharaj President and Chief Executive Officer EDEN PRAIRIE, Minn., Dec 14, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today announced that Gary R. Maharaj has been named President and Chief Executive Officer, effective December
12/14/10
Summary ToggleSurModics to Explore Strategic Alternatives for Its SurModics Pharmaceuticals Business EDEN PRAIRIE, Minn., Dec 14, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today announced that its Board of Directors has authorized the Company to explore strategic alternatives for its
12/13/10
Summary ToggleSurModics Comments on Announcement by Ramius EDEN PRAIRIE, Minn., Dec 13, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today acknowledged the filing of preliminary proxy materials by Ramius Value and Opportunity Advisors LLC, a
11/10/10
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2010 Results EDEN PRAIRIE, Minn., Nov 10, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the fourth quarter and fiscal year ended September 30, 2010.
11/03/10
Summary ToggleSurModics and Edge Therapeutics Collaborate on Development of Sustained-Release Neurological Product Site-Specific Product Designed to Prevent Delayed Complications After Subarachnoid Hemorrhage EDEN PRAIRIE, Minn. & NEWARK, N.J., Nov 03, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry,
11/02/10
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2010 Earnings Conference Call November 10 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Nov 02, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter and
10/14/10
Summary ToggleSurModics Announces Organizational Changes to Reduce Cost Structure and Renew Focus on Business Units EDEN PRAIRIE, Minn., Oct 14, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today initiatives intended to reduce its cost structure and renew its focus on business units.
09/21/10
Summary ToggleSurModics Announces New Board Director EDEN PRAIRIE, Minn., Sep 21, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today the addition of a new member to its board of directors. Effective immediately, Scott R.
07/28/10
Summary ToggleSurModics Reports Third Quarter 2010 Results EDEN PRAIRIE, Minn., Jul 28, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the third quarter ended June 30, 2010.
07/27/10
Summary ToggleSurModics Introduces New StabilBlot(TM) Buffer at American Association for Clinical Chemistry - Clinical Lab Expo EDEN PRAIRIE, Minn., Jul 27, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, will introduce its StabilBlot(TM) Buffer (Protein-Free) product at the American Association for Clinical
07/14/10
Summary ToggleSurModics to Webcast Third Quarter Fiscal Year 2010 Earnings Conference Call July 28 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Jul 14, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter 2010
07/09/10
Summary ToggleSurModics Showcases Drug Delivery Technology at The 37th Annual Meeting and Exposition of the Controlled Release Society EDEN PRAIRIE, Minn., Jul 09, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society (CRS), July 10-14,
07/07/10
Summary ToggleSurModics Signs License Agreement with Clinuvel Pharmaceuticals EDEN PRAIRIE, Minn., Jul 07, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne,
06/01/10
Summary ToggleSurModics Announces Departure of CEO Bruce Barclay EDEN PRAIRIE, Minn., Jun 01, 2010 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that Bruce J Barclay is resigning as President and Chief Executive Officer and from the Board,
05/19/10
Summary ToggleSurModics Receives ISO Certification at SurModics Pharmaceuticals Facilities Facilities In Birmingham, Alabama Receive ISO 9001:2008 and ISO 13485:2003 Certification EDEN PRAIRIE, Minn., May 19, 2010 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that its
05/10/10
Summary ToggleSurModics Showcases New Assay Application at Luminex xMAP Symposium EDEN PRAIRIE, Minn., May 10, 2010 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that it is presenting a scientific poster on the use of its StabilGuard(R) Immunoassay Stabilizer
04/28/10
Summary ToggleSurModics Reports Second Quarter 2010 Results Strong Sequential Growth in Ophthalmology, Diagnostics, and Other Markets EDEN PRAIRIE, Minn., Apr 28, 2010 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for
04/14/10
Summary ToggleSurModics to Webcast Second Quarter Fiscal Year 2010 Earnings Conference Call April 28 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Apr 14, 2010 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter 2010
03/17/10
Summary ToggleSurModics Licenses Ophthalmology Technology to ForSight Labs EDEN PRAIRIE, Minn., Mar 17, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core
03/04/10
Summary ToggleSurModics Announces Organizational and Leadership Changes EDEN PRAIRIE, Minn., Mar 04, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today certain organizational and leadership changes designed to support future growth by better
02/01/10
Summary ToggleSurModics to Webcast Annual Meeting February 8 EDEN PRAIRIE, Minn., Feb 01, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday, February 8, at
01/27/10
Summary ToggleSurModics Reports First Quarter 2010 Results Strong Operating Cash Flow and Continued Diversification EDEN PRAIRIE, Minn., Jan 27, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the first quarter
01/21/10
Summary ToggleSurModics Opens World-Class cGMP Facility for Manufacturing and Development in Birmingham, Alabama New Facility Supports Drug Delivery Customers in Pharmaceutical, Biotech, and Medical Device Industries EDEN PRAIRIE, Minn., Jan 21, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry,
01/13/10
Summary ToggleSurModics to Webcast First Quarter Fiscal Year 2010 Earnings Conference Call January 27 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Jan 13, 2010 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter 2010
11/04/09
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2009 Results Twelfth Consecutive Year of Record Revenue Since IPO EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 4, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the fourth quarter
11/02/09
Summary ToggleSurModics and NuPathe Partner to Develop Novel Long-Acting Parkinson's Treatment EDEN PRAIRIE, Minn. & CONSHOHOCKEN, Pa. --(BUSINESS WIRE)--Nov. 2, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc. , a neuroscience-focused specialty pharmaceutical company, announced
10/28/09
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2009 Earnings Conference Call November 4 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 28, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter and
10/06/09
Summary ToggleSurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech Includes Development and Commercialization of a Sustained Drug Delivery Formulation of Lucentis® and Potentially Other Genentech Compounds EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 6, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies
09/10/09
Summary ToggleSurModics to Present at the CL King Best Ideas Conference EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 10, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that Phil Ankeny , Senior Vice President and Chief Financial Officer, will make a presentation
07/29/09
Summary ToggleSurModics Reports Third Quarter 2009 Results EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 29, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the third quarter ended June 30, 2009 .
07/15/09
Summary ToggleSurModics to Webcast Fiscal 2009 Third Quarter Earnings Conference Call July 29 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 15, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2009 third
05/06/09
Summary ToggleSurModics I-vation(TM) Intravitreal Implant 36 Month Clinical Study Results Presented at the 2009 ARVO Meeting EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May. 6, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that the 36 month Phase I clinical trial results for I-vation™ TA (triamcinolone acetonide) were
04/29/09
Summary ToggleSurModics Reports Second Quarter 2009 Results EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 29, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the second quarter ended March 31, 2009 .
04/15/09
Summary ToggleSurModics to Webcast Fiscal 2009 Second Quarter Earnings Conference Call April 29 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 15, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2009 second
03/04/09
Summary ToggleSurModics Secures Revolving Credit Facility EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 4, 2009-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that it has entered into a credit agreement with Wells Fargo Bank, N.A.
02/02/09
Summary ToggleSurModics Elects Robert C. Buhrmaster Chairman of the Board Kendrick B. Melrose to Retire EDEN PRAIRIE, Minn. --(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that its board of directors has elected Robert C.
01/28/09
Summary ToggleSurModics Reports First Quarter 2009 Results Excellent Operating Cash Flow and Strong Balance Sheet EDEN PRAIRIE, Minn. --(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the first quarter ended December
01/27/09
Summary ToggleSurModics and Nexeon MedSystems to Collaborate on Development of Novel Stent System for Renal Artery Disease Agreement Represents Second Stent Development Collaboration Between SurModics and Nexeon MedSystems EDEN PRAIRIE, Minn. & CHARLESTON, W. Va., Jan 27, 2009 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare
01/20/09
Summary ToggleSurModics to Webcast Annual Meeting February 2 EDEN PRAIRIE, Minn., Jan 20, 2009 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday, February 2, at
01/14/09
Summary ToggleSurModics to Webcast Fiscal 2009 First Quarter Earnings Conference Call January 28 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Jan. 14, 2009 -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2009 first
11/25/08
Summary ToggleSurModics Announces New Board Director EDEN PRAIRIE, Minn., Nov 25, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today the addition of a new member to its board of directors. Mary K.
11/20/08
Summary ToggleSurModics Announces Changes to Its Organizational Structure and Cost-Cutting Initiatives EDEN PRAIRIE, Minn., Nov 20, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today announced changes designed to improve the Company's ability to meet the growing needs of its customers
11/05/08
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2008 Results Eleventh Consecutive Year of Record Revenue Since IPO; Record Annual Revenue in All Three Operating Segments EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 5, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry,
11/04/08
Summary ToggleSurModics Acquires Drug Delivery Assets of PR Pharmaceuticals Broadens Portfolio of Proprietary Drug Delivery Technologies; Adds Multiple Customer Development Programs EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 4, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry,
10/30/08
Summary ToggleSurModics Licenses Hydrophilic Coating for Elixir's Drug-Eluting and Bare Metal Stent Delivery Systems EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 30, 2008--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it is providing advanced hydrophilic coating technology for Elixir Medical Corporation's
10/22/08
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2008 Earnings Conference Call November 5 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter and fiscal year 2008
10/07/08
Summary ToggleSurModics Announces First Human Use of Finale(TM) Prohealing Coating Technology on Nexeon MedSystems' PROTEX(TM) Coronary Stent System EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that the PROTEX(TM) Coronary Stent System incorporating SurModics' proprietary Finale(TM) prohealing coating
09/30/08
Summary ToggleSurModics Acquires CodeLink(TM) Activated Slide Business EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the acquisition of the CodeLink(TM) Activated Slide microarray business from GE Healthcare.
09/17/08
Summary ToggleMerck & Co., Inc. Discontinues License and Research Collaboration Agreement with SurModics No Safety Concerns About I-vation(TM) Platform or I-vation(TM) TA; Reflects Merck's Strategic Review of Its Business and Product Development Portfolio EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 17, 2008--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery
09/15/08
Summary ToggleSurModics to Present at the CL King Best Ideas Conference and UBS Global Life Sciences Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 15, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Phil Ankeny, Senior Vice President and Chief Financial Officer, will make a presentation
08/08/08
Summary ToggleEnrollment in Phase IIb Clinical Trial for I-vation(TM) TA (MK-0140) Suspended Pending Review of Study Design by Merck & Co., Inc. Clinical Data Support Tolerability Profile; Other Development Programs with Merck are Unaffected EDEN PRAIRIE, Minn., Aug 08, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today
07/23/08
Summary ToggleSurModics Reports Third Quarter 2008 Results Strong Operating Cash Flow and Continued Diversification EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 23, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the third fiscal
07/16/08
Summary ToggleSurModics to Webcast Fiscal 2008 Third Quarter Earnings Conference Call July 23 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 16, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2008 third
07/14/08
Summary ToggleSurModics and Brookwood License Nanotechnology Drug Delivery System EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 14, 2008--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its Brookwood Pharmaceuticals subsidiary has licensed lipid nanoparticle technology from
06/25/08
Summary ToggleSurModics Announces Initiation by Merck & Co., Inc. of Phase IIb Clinical Trial for I-vation(TM) TA EDEN PRAIRIE, Minn., Jun 25, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the initiation by Merck & Co., Inc. of a Phase IIb clinical trial to evaluate the safety and
06/10/08
Summary ToggleSurModics to Present at the CapStone Investments Small-Cap Investor Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 10, 2008--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the CapStone Investments
04/24/08
Summary ToggleSurModics to Present at the 2008 Association for Research in Vision and Ophthalmology Meeting EDEN PRAIRIE, Minn., Apr 24, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that two posters and one paper will be presented at the 2008 Association for Research in Vision
04/23/08
Summary ToggleSurModics Purchases Additional Facility to Expand Brookwood Pharmaceuticals' Development and Manufacturing Capacity EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 23, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its Brookwood Pharmaceuticals subsidiary, located in Birmingham, Alabama, has acquired an
04/23/08
Summary ToggleSurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008 EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 23, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the second fiscal quarter ended March 31, 2008.
04/16/08
Summary ToggleSurModics to Webcast Fiscal 2008 Second Quarter Earnings Conference Call April 23 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 16, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2008 second
03/31/08
Summary ToggleSurModics Announces First Human Use of SynBiosys(TM) Biodegradable Polymer on CardioMind Drug-Eluting Stent EDEN PRAIRIE, Minn., Mar 31, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that the SynBiosys(TM) biodegradable drug delivery polymer system was incorporated in a first
01/29/08
Summary ToggleSurModics Announces New Board Directors EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 29, 2008--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the addition of two new members on its board of directors. Robert C. Buhrmaster and Susan E.
01/28/08
Summary ToggleSurModics Expands License Agreement with Merck & Co., Inc. EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 28, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Merck & Co., Inc. has exercised an option to develop and commercialize an additional Merck
01/23/08
Summary ToggleSurModics Reports First Quarter 2008 Results Double-Digit Growth in All Three Operating Segments EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 23, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the first quarter ended
01/16/08
Summary ToggleSurModics to Webcast Fiscal 2008 First Quarter Earnings Conference Call January 23 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 16, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2008 first
01/14/08
Summary ToggleSurModics to Webcast Annual Meeting January 28 Special Guest from Genzyme Pharmaceuticals to Present EDEN PRAIRIE, Minn., Jan 14, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its
11/15/07
Summary ToggleSurModics Announces $35 Million Share Repurchase Authorization EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 15, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its Board of Directors has approved a share repurchase program, authorizing the company to
11/13/07
Summary ToggleSurModics Announces Board Changes EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 13, 2007--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today several changes in the composition of its Board of Directors.
11/07/07
Summary ToggleSurModics to Host Investor Day on November 15th in New York City Webcast is Live at 8:30 a.m. (ET) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 7, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host an Investor Day beginning at 8:30 a.m.
11/06/07
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2007 Results Tenth Consecutive Year of Record Revenue Since 1998 IPO EDEN PRAIRIE, Minn., Nov 06, 2007 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the fourth quarter
10/31/07
Summary ToggleSurModics and OakRiver Technology Collaborate on Advanced Coating Equipment EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 31, 2007--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today an agreement with OakRiver Technology, Inc. to collaborate on the development, manufacture,
10/29/07
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2007 Earnings Conference Call November 6 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Oct 29, 2007 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fourth quarter and
10/18/07
Summary ToggleSurModics Named to Forbes 200 Best Small Companies List EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 18, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, was recently named to Forbes magazine's annual ranking of the 200 Best Small Companies.
09/11/07
Summary ToggleSurModics to Present at the ThinkEquity Partners Growth Conference and the CL King Best Ideas Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 11, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Bruce Barclay, President & CEO, will make a presentation to the investment community at
08/13/07
Summary ToggleSurModics Acquires BioFX Laboratories Complementary Products and Technologies Expand SurModics' Breadth of Offerings for the In Vitro Diagnostics Industry EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 13, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare
08/01/07
Summary ToggleSurModics Acquires Brookwood Pharmaceuticals Strengthens Portfolio of Drug Delivery Technologies for the Pharmaceutical Industry EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 1, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has
07/18/07
Summary ToggleSurModics Reports Third Quarter 2007 Results 19% Growth in Non-CYPHER Revenue EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 18, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the third fiscal quarter ended June 30,
07/11/07
Summary ToggleSurModics to Webcast Fiscal 2007 Third Quarter Earnings Conference Call July 18 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 11, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2007 third
07/10/07
Summary ToggleSurModics and Paragon Intellectual Properties to Collaborate on FINALE(TM) Coated Prohealing Stent to Combat Late Stent Thrombosis SurModics Invests $3.5 Million in Paragon and Its Newly Formed Subsidiary EDEN PRAIRIE, Minn. & CHARLESTON, W. Va., Jul 10, 2007 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX) and Paragon Intellectual Properties, LLC announced today the signing of a license agreement under which the companies
06/27/07
Summary ToggleSurModics to Webcast Ophthalmic License and Research Collaboration Agreement Conference Call Webcast is Live at 7:30 a.m. (CT) Today EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 27, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced that it will host a live webcast of its Ophthalmic License and
06/27/07
Summary ToggleSurModics and Merck Enter Ophthalmic License and Research Collaboration Agreement Includes Both I-vation(TM) TA and I-vation(TM) Platform for Merck Drugs EDEN PRAIRIE, Minn. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--June 27, 2007--SurModics, Inc. (Nasdaq: SRDX) and Merck & Co., Inc. (NYSE: MRK) today announced a License and Research Collaboration Agreement to pursue the joint
05/03/07
Summary ToggleSurModics to Present Five Posters at the Association for Research in Vision and Ophthalmology Meeting EDEN PRAIRIE, Minn., May 03, 2007 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that five posters will be presented at the Association for Research in Vision and Ophthalmology
04/18/07
Summary ToggleSurModics Reports Second Quarter 2007 Results 19% Growth in Non-CYPHER Revenue EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 18, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the second fiscal quarter ended March 31,
04/12/07
Summary ToggleSurModics Signs Agreement with St. Jude Medical EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 12, 2007--SurModics, Inc. (Nasdaq: SRDX) , a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the signing of an expanded corporate technology agreement with St. Jude Medical, Inc.
04/11/07
Summary ToggleSurModics to Webcast Fiscal 2007 Second Quarter Earnings Conference Call April 18 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 11, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2007 second
01/24/07
Summary ToggleSurModics Reports First Quarter 2007 Results 23% Growth in Non-CYPHER Revenue EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 24, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the first quarter ended December 31, 2006.
01/17/07
Summary ToggleSurModics to Webcast Fiscal 2007 First Quarter Earnings Conference Call January 24 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 17, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2007 first
01/15/07
Summary ToggleSurModics to Webcast Annual Meeting January 29 Special Guest from Corning Life Sciences to Present EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 15, 2007--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its
11/17/06
Summary ToggleSurModics Provides Additional Information on its License Agreement with Conor Medsystems EDEN PRAIRIE, Minn., Nov 17, 2006 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today certain additional information about its license agreement with Conor Medsystems, Inc.
11/15/06
Summary ToggleKendrick B. Melrose Honored By NASBA Center for the Public Trust EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 15, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Kendrick B. Melrose, the company's Chairman of the Board, has been honored with the "Being a
11/06/06
Summary ToggleSurModics Commences Share Repurchase Program Adopts 10b5-1 Trading Plan EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 6, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has entered into a 10b5-1 stock purchase agreement covering the
11/01/06
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2006 Results Ninth Consecutive Year of Record Revenue Since 1998 IPO EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 1, 2006--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the fourth quarter
10/19/06
Summary ToggleSurModics to Webcast Fourth Quarter and Fiscal Year 2006 Earnings Conference Call November 1 Business Editors EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 19, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter and fiscal year 2006
10/05/06
Summary ToggleSurModics Strengthens OctoPlus Relationship Participates in IPO EDEN PRAIRIE, Minn., Oct 05, 2006 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that OctoPlus N.V., a biopharmaceutical company based in the Netherlands and
09/20/06
Summary ToggleSurModics to Present at the UBS Global Life Sciences Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 20, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the UBS Global Life Sciences
09/18/06
Summary ToggleSurModics Announces $35 Million Share Repurchase Authorization EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 18, 2006--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its Board of Directors has authorized the repurchase of up to $35 million of the company's
09/12/06
Summary ToggleSurModics to Present at the CL King Best Ideas Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 12, 2006--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the CL King Best Ideas
09/12/06
Summary ToggleSurModics I-vation(TM) Intravitreal Implant Six Month Clinical Study Data Presented at the American Society of Retina Specialists Meeting; Well Tolerated, 100% of Patients Maintained or Improved Vision EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 12, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the presentation of positive six month results from its STRIDE (Sustained Triamcinolone Release
09/07/06
Summary ToggleSurModics and X-Cell Medical Collaborate on Drug Eluting Stent Development; Bravo(TM) Polymer Matrix Licensed for Delivery of 17 beta-Estradiol EDEN PRAIRIE, Minn. & PRINCETON, N.J.--(BUSINESS WIRE)--Sept. 7, 2006--SurModics, Inc. (Nasdaq:SRDX) and X-Cell Medical, Inc. announced today that they have entered into a license agreement for the use of SurModics' Bravo(TM) Drug Delivery Polymer Matrix with X-Cell's ETHOS Drug Eluting Coronary
09/05/06
Summary ToggleSurModics I-vation(TM) Intravitreal Implant Six Month Clinical Study Data to Be Presented at the American Society of Retina Specialists Meeting EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 5, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that six month results from its STRIDE (Sustained Triamcinolone Release for Inhibition of
09/05/06
Summary ToggleSurModics to Present at the 4th Annual ThinkEquity Partners Growth Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 5, 2006--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the 4th Annual ThinkEquity
08/02/06
Summary ToggleSurModics Elects Kendrick B. Melrose Chairman of the Board; Dale R. Olseth to Remain on the Board EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 2, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its Board of Directors has elected Kendrick B.
07/19/06
Summary ToggleSurModics Reports Third Quarter 2006 Results; Record Revenue and Earnings EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 19, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the third fiscal quarter ended June 30, 2006.
07/18/06
Summary ToggleSurModics Expands In Vitro Diagnostics Product Offerings; Obtains Rights to New Products Under an Exclusive Distribution Agreement with DIARECT AG EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 18, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today an expanded relationship with DIARECT AG. Under this new agreement, SurModics will distribute
07/12/06
Summary ToggleSurModics to Webcast Fiscal 2006 Third Quarter Earnings Conference Call July 19 EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 12, 2006-- Webcast is Live at 4:00 p.m. (CT) SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fiscal 2006 third
07/11/06
Summary ToggleSurModics' Hydrophilic Coating Used on CYPHER SELECT(TM) PLUS; The first third-generation drug-eluting stent by Cordis Corporation recently received CE Mark EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 11, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it is providing advanced hydrophilic technology for the delivery system on CYPHER SELECT(TM)
06/28/06
Summary ToggleSurModics and AbbeyMoor Medical to Jointly Develop Drug-Device Convergence Products to Treat Diseases of the Prostate EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 28, 2006--SurModics, Inc. (Nasdaq:SRDX), and AbbeyMoor Medical announced today the signing of an agreement to jointly develop products intended to site specifically deliver therapeutic agents to treat various diseases of the prostate, such as prostatitis
06/07/06
Summary ToggleSurModics to Present at the Goldman Sachs Global Healthcare Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 7, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the Goldman Sachs 27th Annual
06/06/06
Summary ToggleSurModics to Present at the Pacific Growth Equities Life Sciences Growth Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 6, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the Pacific Growth Equities Life
05/15/06
Summary ToggleSurModics Provides Hydrophilic Coating on Xtent's Drug-Eluting Stent Delivery System EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 15, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it is providing advanced hydrophilic technology for the delivery system of Xtent's unique
05/10/06
Summary ToggleSurModics Licenses Ophthalmic Technology to Bausch & Lomb EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 10, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has granted Bausch & Lomb (NYSE:BOL) an exclusive license to patents relating to the use
05/09/06
Summary ToggleSurModics and Donaldson Announce Strategic Marketing and Distribution Relationship with Corning Life Sciences MINNEAPOLIS--(BUSINESS WIRE)--May 9, 2006--SurModics, Inc. (NASDAQ:SRDX) and Donaldson Company, Inc. (NYSE:DCI) today announced a strategic marketing and distribution agreement with Corning Incorporated (NYSE:GLW), through which Corning Life Sciences will provide worldwide marketing and
04/27/06
Summary ToggleSurModics Hires Healthcare Veteran Peter Ginsberg as Vice President of Business Development and Strategic Planning; Other Senior Management Changes Announced EDEN PRAIRIE, Minn., Apr 27, 2006 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Peter L. Ginsberg has joined the company as Vice President of Business Development and
04/19/06
Summary ToggleSurModics Reports Second Quarter 2006 Results; Record Revenue and Non-GAAP Earnings EDEN PRAIRIE, Minn., Apr 19, 2006 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the second fiscal quarter ended March 31, 2006.
04/17/06
Summary ToggleSurModics Licenses Hydrophilic Coating for the Devax AXXESS(TM) Drug-Eluting Bifurcation Stent Delivery System EDEN PRAIRIE, Minn., Apr 17, 2006 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that its advanced Hydrophilic Technology has been licensed to Devax, Inc.
04/11/06
Summary ToggleSurModics to Webcast Fiscal 2006 Second Quarter Earnings Conference Call April 19; Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 11, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fiscal 2006 second quarter conference call on Wednesday,
04/05/06
Summary ToggleSurModics Acquires Biodegradable Polymer Technology EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 5, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has acquired intellectual property covering biodegradable polymer technology from
03/20/06
Summary ToggleSurModics Completes Enrollment of Phase I Clinical Trial of the I-vation(TM) Intravitreal Implant EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--March 20, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the completion of patient enrollment in the STRIDE (Sustained Triamcinolone Release for
03/13/06
Summary ToggleSurModics Names Michael Shoup Vice President of Quality, Regulatory and Clinical Affairs EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--March 13, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Michael J. Shoup has joined the company as Vice President of Quality, Regulatory and
03/06/06
Summary ToggleSurModics Gains Access to Biodegradable Polymer Technology for Site Specific Drug Delivery from InnoCore EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--March 6, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has obtained an option to acquire a license with exclusivity in defined fields from
01/30/06
Summary ToggleSurModics and Donaldson Company Announce Introduction of the First Jointly Developed Nanofiber Cell Culture Product; New Synthetic ECM Mimics 3-D Cell Growth in Body MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2006--SurModics, Inc. (NASDAQ:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, and Donaldson Company, Inc. (NYSE:DCI), a leading worldwide manufacturer of filtration systems, announced today the
01/25/06
Summary ToggleSurModics Reports First Quarter 2006 Results; Sixth Consecutive Quarter of Record Non-GAAP Net Income EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 25, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the first quarter ended December 31, 2005.
01/23/06
Summary ToggleSurModics to Webcast Annual Meeting January 30; Special Guests to Discuss Donaldson Joint Development Project EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 23, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday, January 30, at
01/18/06
Summary ToggleSurModics to Webcast Fiscal 2006 First Quarter Earnings Conference Call January 25; Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 18, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fiscal 2006 first quarter conference call on Wednesday,
01/09/06
Summary ToggleSurModics Names Jan Webster Vice President of Human Resources EDEN PRAIRIE, Minn., Jan 09, 2006 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Jan Marie Webster has joined the company as Vice President of Human Resources. Ms.
11/29/05
Summary ToggleSurModics' Hydrophilic Coating on Medtronic Endeavor(TM) Drug-Eluting Stent Delivery System EDEN PRAIRIE, Minn., Nov 29, 2005 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its advanced hydrophilic technology has been licensed to Medtronic, Inc.
10/26/05
Summary ToggleSurModics Reports Fourth Quarter and Fiscal Year 2005 Results; Eighth Consecutive Year of Record Revenue Since 1998 IPO EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 26, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the fourth quarter and fiscal year ended September 30, 2005.
10/19/05
Summary ToggleSurModics to Webcast Fiscal 2005 Fourth Quarter and Year-End Earnings Conference Call October 26; Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 19, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fiscal 2005 fourth quarter and year-end conference call
09/23/05
Summary ToggleSurModics to Sell Bloomington Facility EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 23, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has entered into an agreement for the sale of its Bloomington, Minnesota facility.
07/26/05
Summary ToggleSurModics to Present at the Adams Harkness Annual Summer Seminar EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 26, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the Adams Harkness 25th Annual
07/20/05
Summary ToggleSurModics Reports Third Quarter Results; Record Revenue and Earnings EDEN PRAIRIE, Minn., Jul 20, 2005 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the third quarter ended June 30, 2005.
07/14/05
Summary ToggleSurModics Enters into Agreement with University of Arizona to Develop Advanced Medical Therapies EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 14, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has entered into a Collaborative Research agreement and license option with The
07/13/05
Summary ToggleSurModics to Webcast Fiscal 2005 Third Quarter Earnings Conference Call July 20; Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Jul 13, 2005 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fiscal 2005 third quarter conference call on Wednesday,
07/12/05
Summary ToggleSurModics Collaborates with CardioMind on Drug Eluting Stent Development EDEN PRAIRIE, Minn. & SUNNYVALE, Calif.--(BUSINESS WIRE)--July 12, 2005--SurModics, Inc. (Nasdaq:SRDX) and CardioMind, Inc. today announced that they have entered into a license agreement for the use of SurModics' ENCORE(TM) Drug Delivery Polymer Matrix with CardioMind's novel ultra low-profile
07/11/05
Summary ToggleSurModics Announces Enrollment of First Patients in Phase I Clinical Trial of the I-vation(TM) Intravitreal Implant for the Treatment of Diabetic Macular Edema EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 11, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that the first clinical implants of its I-vation(TM) Intravitreal Implant have been completed.
06/29/05
Summary ToggleSurModics Names Industry Veteran Paul Lopez President of Ophthalmology Business Unit EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 29, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced the appointment of Paul A. Lopez, 49, as Vice President of SurModics and President of the
06/07/05
Summary ToggleSurModics to Present at the Goldman Sachs Global Healthcare Conference EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 7, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the Goldman Sachs 26th Annual
05/26/05
Summary ToggleDonaldson Company and SurModics Jointly Developing Nanofiber Cell Culture Products New synthetic ECM mimics 3-D cell growth in body MINNEAPOLIS, May 26 /PRNewswire-FirstCall/ -- Donaldson Company, Inc. (NYSE: DCI - News), a leading worldwide manufacturer of filtration systems, and SurModics, Inc. (Nasdaq: SRDX - News), a leading provider of surface modification and drug delivery
05/24/05
Summary ToggleSurModics Makes Strategic Investment in ThermopeutiX; SurModics Also Licenses Hydrophilic and Hemocompatible Coating Technologies to Emerging Medical Device Company Founded by Industry Veteran EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 24, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has invested $1 million in ThermopeutiX, Inc., an early stage company developing novel
04/26/05
Summary ToggleSurModics to Showcase Five Papers at the Association for Research in Vision and Ophthalmology Meeting EDEN PRAIRIE, Minn., Apr 26, 2005 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that five papers will be presented at the Association for Research in Vision and Ophthalmology
04/20/05
Summary ToggleSurModics Reports Second Quarter Results; Record Revenue; Record Profit Excluding One-Time Charge EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 20, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the second quarter ended March 31, 2005.
04/06/05
Summary ToggleSurModics to Webcast Fiscal 2005 Second Quarter Earnings Conference Call April 20; Webcast is Live at 4:00 p.m. CT EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 6, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live Webcast of its fiscal 2005 second quarter conference call on Wednesday,
03/29/05
Summary ToggleSurModics Obtains Exclusive Rights from Rutgers University to Biodegradable Polymers for Ophthalmology EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--March 29, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has obtained an option to acquire an exclusive license from Rutgers, The State
03/21/05
Summary ToggleSurModics Names Barclay Chief Executive Officer EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--March 21, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that its Board of Directors has elected Bruce J Barclay to the position of president and chief
03/09/05
Summary ToggleSurModics to Present at Goldman Sachs Small Cap Growth Conference; Presentation Will Be Webcast Live Friday, March 11 at 10:30 a.m. ET EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--March 9, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, today announced that it will make a presentation to the investment community at the Goldman Sachs Small Cap
01/31/05
Summary ToggleSurModics Names Aron B. Anderson, Ph.D. Chief Scientific Officer EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 31, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, today announced the appointment of Aron B. Anderson, Ph.D. as Vice President and Chief Scientific Officer.
01/27/05
Summary ToggleSurModics To Webcast Annual Meeting January 31 Meeting will be Webcast Live at 4 p.m. (CT), Monday, January 31 EDEN PRAIRIE, Minn., Jan 27, 2005 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, today announced that it will host a live
01/26/05
Summary ToggleSurModics Reports First Quarter Results; Record Revenue and Earnings EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 26, 2005--- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, today reported financial results for the first quarter ended December 31, 2004.
01/20/05
Summary ToggleSurModics Makes Strategic Investment in OctoPlus EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 20, 2005--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, announced today that it has made an equity investment of EUR 3.0 million (approximately $3.9 million) in
01/19/05
Summary ToggleSurModics Acquires InnoRx; Platform Technology for New Ophthalmology Business Unit EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 19, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, announced today that it has acquired InnoRx, Inc., a drug delivery company developing novel therapies for the
01/18/05
Summary ToggleSurModics, Inc. to Webcast Fiscal 2005 First Quarter Earnings Conference Call January 26 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 18, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, today announced that it will host a live Webcast of its fiscal 2005 first
12/16/04
Summary ToggleRubicon Medical and SurModics Collaborate on the Rubicon Filter SALT LAKE CITY, Utah & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Dec. 16, 2004--Rubicon Medical Corporation (OTCBB:RMDC) and SurModics, Inc. (Nasdaq:SRDX) today announced that they have finalized a license agreement for the use of SurModics' advanced hydrophilic coating technology with Rubicon's
10/27/04
Summary ToggleSurModics, Inc. Reports Fourth Quarter and Fiscal Year 2004 Results; Record Quarterly and Fiscal Year Revenue; Record Quarterly Earnings EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 27, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today reported financial results for the fourth quarter and fiscal year ended September 30, 2004.
10/25/04
Summary ToggleSurModics Names David Wood Vice President and General Manager of Its Drug Delivery Business Unit EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 25, 2004--SurModics, Inc. (NASDAQ:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced David S. Wood, 48, will join the company as vice president and general manager of its drug
10/21/04
Summary ToggleSurModics Ranked #20 in Forbes ''200 Best Small Companies'' EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 21, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, was recently named to Forbes magazine's annual ranking of "The 200 Best Small Companies." This year's inclusion
10/18/04
Summary ToggleSurModics, Inc. To Webcast Fiscal Fourth Quarter and Year-End Earnings Conference Call October 27 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 18, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced that it will host a live Webcast of its fiscal 2004 fourth
09/08/04
Summary ToggleSurModics to Present at Morgan Keegan Equity Conference Presentation will be Webcast live Thursday, September 9 at 10:40 a.m. CDT EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 8, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to medical device manufacturers, announced today that it will make a
08/18/04
Summary ToggleBruce Barclay Appointed to SurModics' Board of Directors EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 18, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced that Bruce Barclay, SurModics' president and chief operating officer, has been appointed to its
07/26/04
Summary ToggleSurModics Expands Sales Presence in Europe EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 26, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, announced today that it has entered into an agreement with JVS Sales & Technical Consultants GmbH to expand
07/21/04
Summary ToggleSurModics, Inc. Reports Third Quarter Results Earnings Excluding One-Time Charge Totaled 22 Cents per Share; Fifth Consecutive Quarter with Revenue Exceeding $11 Million EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 21, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical
07/13/04
Summary ToggleSurModics, Inc. Receives ISO Certification EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 13, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced that its Quality Management System has been certified according to procedures listed in ISO
07/07/04
Summary ToggleSurModics, Inc. to Webcast Fiscal Third Quarter Earnings Conference Call July 21 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 7, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced that it will host a live Webcast of its fiscal 2004 third
06/29/04
Summary ToggleSurModics Gains Access to Two Biodegradable Polymer Families From OctoPlus for Medical Device Applications EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 29, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, announced today that it has obtained an option to acquire an exclusive license from OctoPlus to two novel
06/23/04
Summary ToggleSurModics Issues Update on Bloomington Contract Manufacturing Facility EDEN PRAIRIE, Minn., Jun 23, 2004 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced that it expects to record an asset impairment charge against its Bloomington, Minnesota contract
06/08/04
Summary ToggleSurModics, Inc. Introduces Two New Protein Stabilization Products for Microsphere and Microarray Applications EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 8, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, as well as a line of stabilization products used in the in vitro diagnostics industry, today announced the
06/01/04
Summary ToggleSurModics Announces Two New Polymer Technologies for Site Specific Drug Delivery EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 1, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced two new polymer technologies that control the release of drugs from medical device surfaces: the
04/21/04
Summary ToggleSurModics, Inc. Reports Strong Second Quarter Results; 59% Increase in Net Income on a 31% Revenue Gain; Record Six-Month Revenue and Net Income EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 21, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today reported strong financial results for the fiscal second quarter ended March 31, 2004.
04/12/04
Summary ToggleSurModics, Inc. to Webcast Fiscal Second Quarter Earnings Conference Call April 21 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn., Apr 12, 2004 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced that it will host a live Webcast of its fiscal 2004 second
03/31/04
Summary ToggleSurModics Reorganizes to Create Business Units, Emphasize New Technologies EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--March 31, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced a corporate reorganization intended to sharpen its focus on its customers' needs and accelerate
01/26/04
Summary ToggleSurModics, Inc. to Invest in InnoRx, Inc. Companies Collaborating on Drug-Delivery Application in Ophthalmology Market EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 26, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification solutions to medical device manufacturers, today announced an agreement to invest up to $3.5
01/23/04
Summary ToggleSurModics Deepens Management Team with Addition of Vice President and Chief Intellectual Property Counsel Steven J. Keough EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 23, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification solutions to medical device manufacturers, announced that Steven J. Keough, Esq., is joining the company as vice president and chief intellectual property counsel.
01/23/04
Summary ToggleSurModics, Inc. to Showcase Ophthalmology Application at Annual Meeting January 26 Meeting will be Webcast Live at 4 p.m. (CT), Monday, January 26 EDEN PRAIRIE, Minn., Jan 23, 2004 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification solutions for medical device manufacturers, today announced that it will host a live Webcast of its annual
01/21/04
Summary ToggleSurModics, Inc. Reports First Quarter Results; 89% Increase in Net Income on a 50% Revenue Gain EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 21, 2004--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification solutions to medical device manufacturers, today reported its financial results for the fiscal first quarter ended December 31, 2003.
01/14/04
Summary ToggleSurModics, Inc. to Webcast Fiscal First Quarter Earnings Conference Call January 21 EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 14, 2004-- Webcast is Live at 4:00 p.m. (CT) SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification coatings for medical devices, today announced that it will host a live Webcast of its fiscal 2004 first quarter conference call on
01/13/04
Summary ToggleSeraCare Life Sciences, Inc. to Distribute Stabilization Products for SurModics, Inc. SeraCare appointed as an exclusive independent distributor to market and promote SurModics' Stabilization Products EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 13, 2004--SurModics (Nasdaq:SRDX) announced today it has signed an exclusive distribution agreement with SeraCare Life Sciences, Inc.